EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)

Mainak Banerjee, Alexandre Detappe, Twan Lammers

Advanced Drug Delivery Reviews · 2026

DOI: 10.1016/j.addr.2026.115922 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026. Verfasst von Mainak Banerjee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pluridisciplinaire Hubert Curien CNRS UMR 7178, Strasbourg, France; Institut Strauss, 67000 Strasbourg, France; Strasbourg Drug Discovery an…. Hauptthemen laut MEDLINE: Drug Delivery Systems, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degraders (TPDs), including proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD), are among the most promising small-molecule-based drug treatments in oncology. The May 2026 U.S. Food and Drug Administration (FDA) approval of vepdegestrant provides a regulatory milestone for heterobifunctional protein degradation and for PROTAC therapeutics. First-generation TPDs were developed for oral delivery; however, the intrinsic physicochemical properties of TPDs impose constraints on their oral bioavailability, systemic exposure, target-site accumulation, and therapeutic efficacy. As the field transitions toward a second wave of TPD development, nanoparticle-based targeted protein degraders (nano-TPD) are gaining momentum for broadening the therapeutic landscape of protein degradation. In this context, drug delivery systems offer opportunities to overcome key translational barriers by improving pharmacokinetics, tissue distribution, target site localization, cellular uptake, and therapeutic index. Here, we provide an overview of TPD discovery, from early laboratory to (pre-) clinical progress, discuss translational challenges, and suggest advanced drug delivery solutions to help realize the full potential of TPD therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Delivery SystemsAntineoplastic AgentsNeoplasmsHumansProteolysis Targeting ChimeraAnimalsProteolysisNanoparticles

Stichwörter der Autor:innen

Drug deliveryMGDPROTACProteolysiscancer

Substanzen

Proteolysis Targeting ChimeraAntineoplastic Agents

Autor:innen und Institutionen

  • Institut Pluridisciplinaire Hubert Curien CNRS UMR 7178, Strasbourg, France; Institut Strauss, 67000 Strasbourg, France; Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, France; Equipe labelisée Li…
  • Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074 Aachen, Germany. Electronic address: tlammers@ukaachen.de.

Förderung

  • European Research Council

Zitieren

APA

Banerjee, M., Detappe, A., & Lammers, T. (2026). Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD). Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2026.115922

Vancouver

Banerjee M, Detappe A, Lammers T. Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD). Advanced Drug Delivery Reviews. 2026. doi:10.1016/j.addr.2026.115922

BibTeX
@article{Banerjee2026,
  author = {Banerjee, Mainak and Detappe, Alexandre and Lammers, Twan},
  title = {Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  doi = {10.1016/j.addr.2026.115922}
}
Kostenlos starten →